| abstract |
The new application of quinazoline derivative tyrosine kinase inhibitors of the present invention belongs to the field of medical technology, and specifically relates to the compound represented by formula (I), its stereoisomer, its pharmaceutically acceptable salt and its crystal form The new use of R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , L, and n are as defined in the description; the present invention specifically relates to these compounds, pharmaceutical preparations and pharmaceutical compositions containing these compounds in the preparation For the treatment of EGFR_T790M mutation, EGFR_L858R mutation, EGFR_C797S mutation, EGFR_d746‑750 mutation, EGFR_T790M/L858R mutation, EGFR_T790M/C797S mutation, EGFR_T790M/d746‑750 mutation, EGFR_C797S/L858R mutation, EGFR_L858R/C5679 mutation ‑750 mutation, EGFR_L858R/T790M/C797S mutation, EGFR_d746‑750/T790M/C797S mutation or EGFR_d746‑750/L858R/C797S tumor patient's use in medicine. |